论文部分内容阅读
据悉,2013年7月,传统药企康美药业股份有限公司和广州医药集团已经取得商务部获准直销的批复。两大医药集团进军直销的消息,使得药企切入直销的现实性与前景再次成为众人热议的焦点。传统药企闯直销在业界此前也有过先例,比如哈药集团,但是结果却不太理想,争议也颇多。而经《中国直销》记者了解,目前康美和广药的直销业务尚处于理论探讨阶段,前景不明。对于康美以及广药进军直销的意图、具体做法以及未来前景等相关问题,都值得深入探讨和思考。因此,《中国直销》本期特邀直销业界的几位专家进行发散性讨论。
It is reported that in July 2013, the traditional pharmaceutical companies Kang Mei Pharmaceutical Co., Ltd. and Guangzhou Pharmaceutical Group have obtained approval of the Ministry of Commerce direct marketing approval. The two major pharmaceutical groups to enter the direct selling news, making the reality of pharmaceutical companies cut into the direct marketing and prospects once again become the focus of public hot. Traditional pharmaceutical companies break through direct sales in the industry had also had precedents, such as Harbin Pharmaceutical Group, but the result is not ideal, a lot of controversy. The “China direct marketing” reporter understands that at present, the United States and GPR’s direct sales business is still in the theoretical stage of discussion, the future is unknown. It is worth discussing and thinking deeply about the intent, specific practices and prospects of the future of the Hong Mei and GPI to enter the market. Therefore, “China’s direct sales” this issue invited several experts in the direct selling industry to conduct divergent discussions.